Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study

Acta Oncologica

Volumn 54, Issue 7, 2015, Pages 1001-1007

  Bentzen, Jens ^a   Toustrup, Kasper ^c   Eriksen, Jesper Grau ^b   Primdahl, Hanne ^c   Andersen, Lisbeth Juhler ^d   Overgaard, Jens ^c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; NIMORAZOLE; PROTEIN P16; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; DRY THROAT; DYSPHAGIA; ENTERIC FEEDING; EVENT FREE SURVIVAL; FEASIBILITY STUDY; FEMALE; FIBROSIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MOUTH SQUAMOUS CELL CARCINOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NECK FIBROSIS; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT OUTCOME; WART VIRUS; XEROSTOMIA; ADVERSE EFFECTS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HEAD AND NECK NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NIMORAZOLE;

EID: 84930904329     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2014.992547     Document Type: Article

References (29)

1. Overgaard J. Hypoxic modifi cation of radiotherapy in squamous cell carcinoma of the head and neck - a systematic review and meta-analysis. Radiother Oncol 2011; 100: 22-32.
2. Bourhis J, Overgaard J, Audry H, Ang K K, Saunders M, Bernier J, et al. Meta-analysis of Radiotherapy in Carcinomas of Head and Neck (MARCH) Collaborative Group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet 2006; 368: 843-54.
3. Pignon JP, Bourhis J, Domenge C, Design é L. Chemotherapy added to locoregional treatment for head and neck squamous- cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355: 949-55.
4. Pignon JP, le Maî tre A, Maillard E, Bourhis J, MACH-N C Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14.
5. Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): Acomprehensive analysis by tumour site. Radiother Oncol 2011; 100: 33-40.
6. Overgaard J, Hansen H S, Andersen AP, H jelm-Hansen M, J ø rgensen K, Sandberg E, et al. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: Report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 1989; 16: 1065-8.
7. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, et al. Arandomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998; 46: 135-46.
8. Lassen P, Eriksen JG, H amilton-Dutoit S, Tramm T, Alsner J, Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27: 1992-8.
9. Overgaard J, Hansen H S, Specht L, Overgaard M, Grau C, Andersen E, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003; 362: 933-40.
10. Mortensen HR, Overgaard J, Specht L, Overgaard M, Johansen J, Evensen JF, et al. Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6 & 7 randomised trial with accelerated radiotherapy for head and neck cancer. Radiother Oncol 2012; 103: 69-75. Mortensen HR [11], Overgaard J, Jensen K, Specht L, Overgaard M, Johansen J, et al. Factors associated with acute and late dysphagia in the DAHANCA 6 & 7 randomized trial with accelerated radiotherapy for head and neck cancer. Acta Oncol 2013; 52: 1535-42.
11. Overgaard J, Khan A R. Selective enhancement of radiation response in a C3H mammary carcinoma by cisplatin. Cancer Treat Rep 1981; 65: 501-3.
12. Bentzen S M, Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 2007; 25: 4096-103.
13. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG analysis. J Clin Oncol 2008; 26: 3582-9.
14. Adelstein DJ, Li Y, Adams GL, Wagner H, J r., Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21: 92-8.
15. Thomas G M. Improved treatment for cervical cancer - concurrent chemotherapy and radiotherapy. N Engl J Med 1999; 340: 1198-200.
16. Chan A T, Teo PM, Ngan RK, Leung TW, Lau WH, Zee B, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in loco regionally advanced nasopharyngeal carcinoma: Progression-free survival analysis of a phase III randomized trial. J Clin Oncol 2002; 20: 2038-44.
17. Ang K K, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-T â n PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
18. Metwally MA, Frederiksen KD, Overgaard J. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Acta Oncol 2014; 53: 654-61.
19. Gr é goire V, Levendag P, Ang KK, Bernier J, Braaksma M, Budach V, et al. CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines. Radiother Oncol 2003; 69: 227-36.
20. Michiels S, Le Ma î tre A, Buyse M, Burzykowski T, Maillard E, Bogaerts J, et al. MARCH and MACH-NC Collaborative Groups. Surrogate endpoints for overall survival in locally advanced head and neck cancer: Meta-analyses of individual patient data. Lancet Oncol 2009; 10: 341-50.
21. Lassen P. The role of human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. Radiother Oncol 2010; 95: 371-80.
22. Bourhis J, Sire C, Graff P, Gr é goire V, Maingon P, Calais G, Gery B, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): An open-label phase 3 randomised trial. Lancet Oncol 2012; 13: 145-53.
23. Ang KK, Zhang Q, Rosenthal DI, N guyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 2014; 32: 2940-50.
24. Rischin D, Peters L J, O ' Sullivan B, Giralt J, Fisher R, Yuen K, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): Aphase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010; 28: 2989-95.
25. Peters L J, O ' Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, Bernier J, et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: Results from TROG 02.02. J Clin Oncol 2010; 28: 2996-3001.
26. Eriksen JG, Maare C, Johansen J, Primdahl H, Evensen JF, Kristensen CA, et al. DAHANCA19: Arandomized phase III study of primary (chemo-) radiotherapy and zalutumumab in head and neck carcinomas. Radiother Oncol 2014; 111(Suppl 1): 154-5.
27. Garden A S, Harris J, Trotti A, Jones CU, Carrascosa L, Cheng JD, et al. Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Aphase II trial of the radiation therapy oncology group (RTOG 99-14). Int J Radiat Oncol Biol Phys 2008; 71: 1351-5.
28. Machtay M, Moughan J, Farach A, M artin-O' Meara E, Galvin J, Garden AS, et al. Hypopharyngeal dose is associated with severe late toxicity in locally advanced head-andneck cancer: An RTOG analysis. Int J Radiat Oncol Biol Phys 2012; 84: 983-9.
29. Koyfman S A, Adelstein D J. Enteral feeding tubes in patients undergoing defi nitive chemoradiation therapy for head-andneck cancer: Acritical review. Int J Radiat Oncol Biol Phys 2012; 84: 581-9.